Official registry condition

COVID-19 peptide trials

5 selected ClinicalTrials.gov records carrying the official condition label COVID-19. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

5 selected records.

Connected peptides

4 profiles.

Registry update years

2022–2026 in selected records.

Indication intelligence

Selected evidence landscape

Trial phases2

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses2

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 102 selected PubMed records and 13 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern COVID-19 unless their own cited source says so.

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT04382755

PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.

PeptideScanner change date
November 15, 2026
Cited source date
September 14, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04397718

PeptideScanner retained ClinicalTrials.gov record NCT04397718 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-06-06, and PeptideScanner's reviewed identity mapping was degarelix.

PeptideScanner change date
November 15, 2026
Cited source date
June 6, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04428008

PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

PeptideScanner change date
November 15, 2026
Cited source date
April 21, 2026
Evidence lane
Clinical trials

Attributed registry records

Selected records

All trial facets →